[go: up one dir, main page]

MX2019004999A - Derivados biciclo hetorociclicos sustituidos, utiles como inhibidores del canal de potasio medular externo renal (romk). - Google Patents

Derivados biciclo hetorociclicos sustituidos, utiles como inhibidores del canal de potasio medular externo renal (romk).

Info

Publication number
MX2019004999A
MX2019004999A MX2019004999A MX2019004999A MX2019004999A MX 2019004999 A MX2019004999 A MX 2019004999A MX 2019004999 A MX2019004999 A MX 2019004999A MX 2019004999 A MX2019004999 A MX 2019004999A MX 2019004999 A MX2019004999 A MX 2019004999A
Authority
MX
Mexico
Prior art keywords
useful
romk
inhibitors
hetorocyclic
medular
Prior art date
Application number
MX2019004999A
Other languages
English (en)
Other versions
MX382290B (es
Inventor
Scott Priestley Eldon
Dnyanoba Yadav Navnath
S Bhide Rajeev
Panda Manoranjan
Gunaga Prashantha
Richter Jeremy
Onkardas Bora Rajesh
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2019004999A publication Critical patent/MX2019004999A/es
Publication of MX382290B publication Critical patent/MX382290B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se dan a conocer compuestos de la Fórmula (I) (ver Fórmula) o una sal de los mismos, en donde R1 es (II) o (III) cada W es independientemente NR1b u O; Z es un enlace o CHR1d; y R1, R2, Rd, R3, L1, L2, R1a, R1b, R1c y n se definen aquí. También se describen métodos para usar tales compuestos como inhibidores de ROMK, y composiciones farmacéuticas que comprenden los compuestos. Estos compuestos son útiles en el tratamiento de enfermedades cardiovasculares.
MX2019004999A 2016-11-03 2017-11-02 Derivados biciclo hetorocíclicos sustituidos, útiles como inhibidores del canal de potasio medular externo renal (romk). MX382290B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201611037609 2016-11-03
PCT/US2017/059642 WO2018093569A1 (en) 2016-11-03 2017-11-02 Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors

Publications (2)

Publication Number Publication Date
MX2019004999A true MX2019004999A (es) 2019-08-05
MX382290B MX382290B (es) 2025-03-13

Family

ID=60413273

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004999A MX382290B (es) 2016-11-03 2017-11-02 Derivados biciclo hetorocíclicos sustituidos, útiles como inhibidores del canal de potasio medular externo renal (romk).

Country Status (14)

Country Link
US (1) US10723723B2 (es)
EP (1) EP3535258B1 (es)
JP (1) JP7102404B2 (es)
KR (1) KR102530512B1 (es)
CN (1) CN110139862B (es)
AU (1) AU2017362870A1 (es)
BR (1) BR112019008824A2 (es)
CA (1) CA3042380A1 (es)
EA (1) EA201991095A1 (es)
ES (1) ES2902527T3 (es)
IL (1) IL266326A (es)
MX (1) MX382290B (es)
SG (1) SG11201903871TA (es)
WO (1) WO2018093569A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3630752T3 (da) 2017-06-01 2021-08-09 Bristol Myers Squibb Co Substituerede nitrogenholdige forbindelser
CN113557235B (zh) 2019-03-06 2025-08-08 C4医药公司 用于药物治疗的杂环化合物
CN113666920B (zh) * 2020-04-14 2025-10-03 浙江华海药业股份有限公司 苯并恶唑类化合物制备方法及其在医药领域的应用
US20230286904A1 (en) * 2020-07-02 2023-09-14 Bridgene Biosciences, Inc. Inhibitors of yap/taz-tead oncoproteins, synthesis and use thereof
WO2022090481A1 (en) 2020-11-02 2022-05-05 Boehringer Ingelheim International Gmbh Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6032074B2 (ja) 1980-06-25 1985-07-25 芦森工業株式会社 管路
MXPA04009434A (es) * 2002-04-03 2005-01-25 Allergan Inc (3z)-3- (3 -hidroisobenzofuran- 1-iliden) -1, 3-dihidro- 2h-indol -2-onas como inhibidores de cinasa.
CA2524321A1 (en) * 2003-05-01 2004-11-18 Bristol-Myers Squibb Company Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
US20050004133A1 (en) 2003-06-05 2005-01-06 Makings Lewis R. Modulators of VR1 receptor
MX2008012482A (es) * 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
WO2007122482A1 (en) 2006-04-20 2007-11-01 Pfizer Products Inc. Fused phenyl amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases
US7842713B2 (en) 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
CA2697382A1 (en) 2007-08-27 2009-03-05 Abbott Gmbh & Co. Kg 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
UA106724C2 (uk) 2008-06-30 2014-10-10 Янссен Фармацевтика Нв Спосіб отримання заміщених піримідинових похідних
US8673920B2 (en) 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8334315B2 (en) * 2009-05-07 2012-12-18 Gruenenthal Gmbh Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands
EP2430018B1 (en) 2009-05-15 2013-07-03 Novartis AG Benzoxazolone derivatives as aldosterone symthase inhibitors
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
ES2687177T3 (es) 2010-02-19 2018-10-24 Arizona Board Of Regents, A body corporate of the State of Arizona acting, For and on behalf of Arizona State University Inhibidores de radicales multifuncionales y su uso
US9073882B2 (en) 2010-10-27 2015-07-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9056859B2 (en) 2010-10-29 2015-06-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
RU2014110401A (ru) 2011-08-19 2015-09-27 Мерк Шарп И Доум Корп. Ингибиторы внешнего медуллярного калиевого канала почек
US9527830B2 (en) 2011-09-16 2016-12-27 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013062900A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2771005B1 (en) 2011-10-25 2016-05-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9493474B2 (en) 2011-10-31 2016-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773206B1 (en) 2011-10-31 2018-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9139585B2 (en) 2011-10-31 2015-09-22 Merck Sharp & Dohme Corp. Inhibitors of the Renal Outer Medullary Potassium channel
EP2790511B1 (en) 2011-12-16 2016-09-14 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2647628A1 (en) 2012-04-02 2013-10-09 Almirall, S.A. Substituted tricyclic compounds with activity towards ep1 receptors
PE20142366A1 (es) 2012-05-30 2015-01-10 Hoffmann La Roche Compuestos triazolo como inhibidores de pde 10
WO2014015495A1 (en) 2012-07-26 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
CA2881357C (en) 2012-08-21 2020-12-08 Peter Maccallum Cancer Institute Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof
EP2925322B1 (en) 2012-11-29 2018-10-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9573961B2 (en) 2012-12-19 2017-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
WO2014126944A2 (en) 2013-02-18 2014-08-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9765074B2 (en) 2013-03-15 2017-09-19 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9777872B2 (en) 2013-07-05 2017-10-03 Jeffrey Scott Adler Fluid spill containment, location, and real time notification device with cable based sensor
EP3027625B1 (en) 2013-07-31 2018-05-30 Merck Sharp & Dohme Corp. Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure
WO2015065866A1 (en) 2013-10-31 2015-05-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP3083573B1 (en) * 2013-12-18 2024-08-07 Merck Sharp & Dohme LLC Inhibitors of the renal outer medullary potassium channel
WO2015090579A1 (en) 2013-12-18 2015-06-25 Grünenthal GmbH Pyrazolyl-based carboxamides iv
WO2015096035A1 (en) 2013-12-24 2015-07-02 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2015103756A1 (en) 2014-01-09 2015-07-16 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
CN106488912A (zh) 2014-07-14 2017-03-08 默沙东公司 肾外髓质钾通道的抑制剂
WO2016008064A1 (en) 2014-07-14 2016-01-21 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
US20170275302A1 (en) 2014-10-14 2017-09-28 Alexander Pasternak Inhibitors of the renal outer medullary potassium channel
WO2016065582A1 (en) 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016069428A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065603A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065602A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
CA2966788A1 (en) 2014-12-08 2016-06-16 Shanghai Hengrui Pharmaceutical Co., Ltd. Pyridinecarboxamide derivatives, preparation method therefor and pharmaceutical uses thereof
CN105693706B (zh) * 2014-12-10 2019-11-22 江苏恒瑞医药股份有限公司 异苯并呋喃酮类衍生物、其制备方法及其在医药上的应用
US10513518B2 (en) 2015-01-29 2019-12-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
US10851108B2 (en) 2016-04-20 2020-12-01 Bristol-Myers Squibb Company Substituted bicyclic heterocyclic compounds
DK3630752T3 (da) 2017-06-01 2021-08-09 Bristol Myers Squibb Co Substituerede nitrogenholdige forbindelser

Also Published As

Publication number Publication date
EA201991095A1 (ru) 2019-09-30
WO2018093569A4 (en) 2018-07-12
US20190248769A1 (en) 2019-08-15
JP7102404B2 (ja) 2022-07-19
CA3042380A1 (en) 2018-05-24
AU2017362870A1 (en) 2019-06-20
EP3535258B1 (en) 2021-11-24
JP2020504706A (ja) 2020-02-13
IL266326A (en) 2019-06-30
KR102530512B1 (ko) 2023-05-08
MX382290B (es) 2025-03-13
US10723723B2 (en) 2020-07-28
ES2902527T3 (es) 2022-03-28
KR20190075110A (ko) 2019-06-28
EP3535258A1 (en) 2019-09-11
CN110139862B (zh) 2024-01-16
SG11201903871TA (en) 2019-05-30
CN110139862A (zh) 2019-08-16
WO2018093569A1 (en) 2018-05-24
BR112019008824A2 (pt) 2019-07-09

Similar Documents

Publication Publication Date Title
CL2020003007A1 (es) Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017)
MX2017007044A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
MX2021005714A (es) Nuevos compuestos heterociclicos.
SV2016005137A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
MX2019004999A (es) Derivados biciclo hetorociclicos sustituidos, utiles como inhibidores del canal de potasio medular externo renal (romk).
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
CR20170524A (es) Amidas heterocíclicas como inhibidores de quinasa.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CO2019013589A2 (es) Compuestos que contienen nitrógeno sustituido
CR20160191A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
CR20140079A (es) Aminoquinazolinas como inhibidores de quinasa
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
SV2017005381A (es) Compuestos de imidazopiridazina
MX389753B (es) Compuestos triciclicos y su uso como inhibidores de la fosfodiesterasa
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
CR20170496A (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
MX374383B (es) Derivados de carboxamida como inhibidores de smurf-1
MX2019009606A (es) Bis-compuestos para dispositivos opticamente activos.
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
SV2016005293A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
ECSP19013196A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
MX390507B (es) Compuestos de amida y su uso.